Quantum-Si Provides Business Updates at the 40th Annual J.P. Morgan Healthcare Conference
January 10 2022 - 4:10PM
Business Wire
Jan. 10, 2022--Quantum-Si Incorporated (Nasdaq: QSI)
(“Quantum-Si,” or the “Company”), a life sciences tools company
commercializing a single molecule protein sequencing platform,
today announced that management will discuss the following business
updates at the 40th Annual J.P. Morgan Healthcare Conference.
Commercial update
- Quantum-Si has established list prices for its end-to-end
protein sequencing platform as follows:
- $70,000 for the PlatinumTM Single Molecule Analyzer
- $20,000 for the CarbonTM automated sample preparation
instrument
- Company will begin taking pre-orders in the 1st half of 2022
for delivery at full commercial release.
Technology update
- Quantum-Si posted its first technical manuscript on bioRxiv.
The manuscript, titled “Real-time dynamic single-molecule protein
sequencing on an integrated semiconductor device,” provides a
detailed overview of Time Domain SequencingTM enabling
massively-parallel single molecule protein sequencing at individual
amino acid resolution on a semiconductor chip.
- Updates on the progress with External Early Access
Partners
Insight into 2022 Company Strategic Focus
Since completing its business combination with HighCape Capital
Acquisition Corp on June 10, 2021, Quantum-Si has successfully
launched its early access program, strengthened its management team
and board of directors, and expanded its infrastructure to support
commercialization and growth over the coming years.
“The Company entered a tremendous growth phase in 2021 enabled
by the capital raised taking the company public with expansion of
the team across all areas of the Company,” said John Stark, Chief
Executive Officer of Quantum-Si. “We look forward to discussing our
progress and building upon our strong momentum as we continue our
commercialization path in 2022.”
Webcast Information
To access the live webcast of Quantum-Si’s virtual presentation
at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday,
January 12, 2022 at 4:30 pm ET, please use the webcast link
available in the Events & Presentations section of the
Quantum-Si investor website. A replay of the webcast will be
available for a limited period following the conference.
About Quantum-Si Incorporated
Founded by Dr. Jonathan Rothberg in 2013, Quantum-Si is focused
on revolutionizing the growing field of proteomics. The Company's
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable single molecule
next-generation protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing.
Forward Looking Statements
This press release includes "forward-looking statements" within
the meaning of the "safe harbor" provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of the Company may differ from its expectations, estimates,
and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as "expect," "estimate," "project," "budget," "forecast,"
"anticipate," "intend," "plan," "may," "will," "could," "should,"
"believes," "predicts," "potential," "continue," and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation, the
Company's expectations with respect to future performance and
development and commercialization of products and services. These
forward-looking statements involve significant risks and
uncertainties that could cause actual results to differ materially
from those discussed in the forward-looking statements. Most of
these factors are outside the Company's control and are difficult
to predict. Factors that may cause such differences include, but
are not limited to: the impact of COVID-19 on the Company's
business; the inability to maintain the listing of the Company's
shares of Class A common stock on The Nasdaq Stock Market LLC; the
ability to recognize the anticipated benefits of the recently
completed business combination, which may be affected by, among
other things, competition and the ability of the Company to grow
and manage growth profitably and retain its key employees; changes
in applicable laws or regulations; the ability of the Company to
raise financing in the future; the success, cost and timing of the
Company's product development and commercialization activities; the
potential attributes and benefits of the Company's products and
services; the Company's ability to obtain and maintain regulatory
approval for its products, and any related restrictions and
limitations of any approved product; the Company's ability to
identify, in-license or acquire additional technology; the
Company's ability to maintain its existing lease, license,
manufacture and supply agreements; the Company's ability to compete
with other companies currently marketing or engaged in the
development and commercialization of products and services that the
Company is developing; the size and growth potential of the markets
for the Company's future products and services, and its ability to
serve those markets, either alone or in partnership with others;
the pricing of the Company's products and services following
anticipated commercial launch; the Company's estimates regarding
future expenses, future revenue, capital requirements and needs for
additional financing; the Company's financial performance; and
other risks and uncertainties indicated from time to time in the
Company's filings with the U.S. Securities and Exchange Commission.
The Company cautions that the foregoing list of factors is not
exclusive. The Company cautions readers not to place undue reliance
upon any forward-looking statements, which speak only as of the
date made. The Company does not undertake or accept any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220110005875/en/
Investor Juan Avendano Mike Cavanaugh (617) 877-9641
ir@quantum-si.com
Media Cammy Duong (203) 682-8380 QSI-PR@westwicke.com
Quality Systems (NASDAQ:QSII)
Historical Stock Chart
From Jul 2024 to Aug 2024
Quality Systems (NASDAQ:QSII)
Historical Stock Chart
From Aug 2023 to Aug 2024